

# Bit Market Services

Informazione Regolamentata n. 0696-129-2015	Data/Ora Ricezione 29 Ottobre 2015 07:28:50	MTA
---	---	-----

Societa' : CTI BIOPHARMA

Identificativo : 64741

Informazione  
Regolamentata

Nome utilizzatore : CELLN02 - Bell

Tipologia : IRAG 09

Data/Ora Ricezione : 29 Ottobre 2015 07:28:50

Data/Ora Inizio : 29 Ottobre 2015 07:43:51

Diffusione presunta

Oggetto : CTI BioPharma Corp.: CTI BioPharma to  
Report Third Quarter 2015 Financial  
Results on November 5, 2015

*Testo del comunicato*

Vedi allegato.



## **CTI BioPharma to Report Third Quarter 2015 Financial Results on November 5, 2015**

**SEATTLE, Wash., October 29, 2015**--CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its third quarter 2015 financial results on Thursday, November 5, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EST (1:30 p.m. PST). Access to the event can be obtained as follows:

Thursday, November 5  
1:30 p.m. PST/4:30 p.m. EST/10:30 p.m. CET  
1-800-344-6491 (domestic)  
+1 785-830-7988 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, [www.ctibiopharma.com](http://www.ctibiopharma.com). Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is 4854945. The telephone replay will be available until Thursday, November 12, 2015.

### **About CTI BioPharma Corp.**

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit [www.ctibiopharma.com](http://www.ctibiopharma.com).

Source: CTI BioPharma Corp.

###

### **Contacts:**

Monique Greer  
+1 206-272-4343  
[mgreer@ctibiopharma.com](mailto:mgreer@ctibiopharma.com)

Ed Bell  
+1 206-272-4345  
[ebell@ctibiopharma.com](mailto:ebell@ctibiopharma.com)

Fine Comunicato n.0696-129

Numero di Pagine: 3